As 2026 begins, global urological associations are updating clinical guidelines to incorporate next-generation sublingual phosphodiesterase-5 inhibitors that bypass traditional gastrointestinal metabolism. These regulatory updates from the FDA and European Medicines Agency focus on reducing the onset time of medication while minimizing interactions with dietary fats and alcohol. This clinical...
Portuguese 
English
Arabic
French
Spanish
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek